Document:

EMPLOYMENT
AGREEMENT

 

THIS
EMPLOYMENT AGREEMENT (“Agreement”) is made as of August 21, 2017 by and between AgeX Therapeutics, Inc (“AgeX”),
a Delaware corporation, and Hal Sternberg, Ph.D. (“Employee”).

 

1.
Engagement; Position and Duties.

 

(a)
AgeX agrees to employ Employee in the position described on Exhibit A (which Exhibit A is a part of this Agreement) effective
as of the date of this Agreement. Employee shall perform the duties and functions described on Exhibit A and such other duties
as the executive(s) to whom Employee reports or the Board of Directors of AgeX may from time to time determine. Employee shall
devote Employee’s best efforts, skills, and abilities, on a full-time basis, exclusively to the business of AgeX and its
Related Companies pursuant to, and in accordance with, business policies and procedures, as fixed from time to time by the Board
of Directors (the “Policies”). Employee covenants and agrees that Employee will faithfully adhere to and fulfill the
Policies, including any changes to the Policies that may be made in the future. Employee may be provided with a copy of AgeX’s
employee manual (the “Manual”) which contains the Policies. AgeX may change its Policies from time to time, in which
case Employee will be notified of the changes in writing by a memorandum, a letter, or an update or revision of AgeX’s employee
manual.

 

(b)
Performance of Services for Related Companies. In addition to the performance of services for AgeX, Employee shall, to the
extent so required by AgeX, also perform services for one or more members of a consolidated group of which AgeX is a part (“Related
Company”), provided that such services are consistent with the kind of services Employee performs or may be required to
perform for AgeX under this Agreement. If Employee performs any services for any Related Company, Employee shall not be entitled
to receive any compensation or remuneration in addition to or in lieu of the compensation and remuneration provided under this
Agreement on account of such services for the Related Company. The Policies will govern Employee’s employment by AgeX and
any Related Companies for which Employee is asked to provide Services. In addition, Employee covenants and agrees that Employee
will faithfully adhere to and fulfill such additional policies as may be established from time to time by the board of directors
of any Related Company for which Employee performs services, to the extent that such policies and procedures differ from or are
in addition to the Policies adopted by AgeX.

 

(c)
No Conflicting Obligations. Employee represents and warrants to AgeX and each Related Company that Employee is under no obligations
or commitments, whether contractual or otherwise, that are inconsistent with Employee’s obligations under this Agreement
or that would prohibit Employee, contractually or otherwise, from performing Employee’s duties as under this Agreement and
the Policies.

 

(d)
No Unauthorized Use of Third Party Intellectual Property. Employee represents and warrants to AgeX and each Related Company
that Employee will not use or disclose, in connection with Employee’s employment by AgeX or any Related Company, any patents,
trade secrets, confidential information, or other proprietary information or intellectual property as to which any other person
has any right, title or interest, except to the extent that AgeX or a Related Company holds a valid license or other written permission
for such use from the owner(s) thereof. Employee represents and warrants to AgeX and each Related Company that Employee has returned
all property and confidential information belonging to any prior employer.

 

    	 

    	 

    

 

2.
Compensation

 

(a)
Salary. During the term of this Agreement, AgeX shall pay to the Employee the salary shown on Exhibit A. Employee’s
salary shall be paid in equal biweekly installments, consistent with AgeX’s regular salary payment practices. Employee’s
salary may be increased from time-to-time by AgeX, in AgeX’s sole and absolute discretion, without affecting this Agreement.

 

(b)
Bonus. Employee may be eligible for an annual bonus, as may be approved by the Board of Directors in its discretion,
based on Employee’s performance and achievement of goals or milestones set by the Board of Directors from time to time.
Employee agrees that the Board of Directors of AgeX may follow the recommendations of its Compensation Committee in determining
whether to a award bonus or to establish performance goals or milestones. Employee also agrees that the Board of Directors and
AgeX are not obligated to adopt any bonus plan, to maintain in effect any bonus plan that may now be in effect or that may be
adopted during the term of Employee’s employment, or to pay Employee a bonus unless a bonus is earned under the terms and
conditions of any bonus plan adopted by AgeX or Employee attaining the bonus performance goals for Employee established by the
Board of Directors or its Compensation Committee; provided, that unless otherwise provided in a bonus plan or award, a bonus shall
not be earned until paid and shall not be paid unless Employee remains an employee of the Company on the date of payment.

 

(c)
Expense Reimbursements. AgeX or a Related Company shall reimburse Employee for reasonable travel and other business
expenses (but not expenses of commuting to work) incurred by Employee in the performance of Employee’s duties under this
Agreement, subject to the Policies and procedures in effect from time to time, and provided that Employee submits supporting vouchers.

 

(d)
Benefit Plans. Employee may be eligible (to the extent Employee qualifies) to participate in certain retirement, pension,
life, health, accident and disability insurance, stock option plan or other similar employee benefit plans which may be adopted
by AgeX (or a Related Company) for its employees. AgeX and the Related Companies have the right, at any time and without any amendment
of this Agreement, and without prior notice to or consent from Employee, to adopt, amend, change, or terminate any such benefit
plans that may now be in effect or that may be adopted in the future, in each case without any further financial obligation to
Employee. Any benefits to which Employee may be entitled under any benefit plan shall be governed by the terms and conditions
of the applicable benefit plan, and any related plan documents, as in effect from time to time. If Employee receives any grant
of stock options or restricted under any stock option plan or stock purchase plan of AgeX or any Related Company, the terms and
conditions of the stock options or restricted stock, and Employee’s rights with respect to the stock options or restricted
stock, shall be governed by (i) the terms of the applicable stock option or stock purchase plan, as the same may be amended from
time to time, and (ii) the terms and conditions of any stock option agreement or stock purchase agreement and related agreements
that Employee may sign or be required to sign with respect to the stock options or restricted stock.

 

(e)
Vacation; Sick Leave. Employee shall be entitled to the number of days of vacation and sick leave (without reduction
in compensation) during each calendar year shown on Exhibit A or as may be provided by the Policies. Employee’s vacation
shall be taken at such time as is consistent with the needs and Policies of AgeX and its Related Companies. All vacation days
and sick leave days shall accrue annually based upon days of service. Employee’s right to leave from work due to illness
is subject to the Policies and the provisions of this Agreement governing termination due to disability, sickness or illness.
The Policies governing the disposition of unused vacation days and sick leave days remaining at the end of AgeX’s fiscal
year shall govern whether unused vacation days or sick leave days will be paid, lost, or carried over into subsequent fiscal years.

 

    	2

    	 

    

 

3.
Competitive Activities. During the term of Employee’s employment, and for one year thereafter, Employee shall not, for
Employee or any third party, directly or indirectly employ, solicit for employment or recommend for employment any person employed
by AgeX or any Related Company. During the term of Employee’s employment, Employee shall not, directly or indirectly as
an employee, contractor, officer, director, member, partner, agent, or equity owner, engage in any activity or business that competes
or could reasonably be expected to compete with the business of AgeX or any Related Company. Employee acknowledges that there
is a substantial likelihood that the activities described in this Section would (a) involve the unauthorized use or disclosure
of AgeX’s or a Related Company’s Confidential Information and that use or disclosure would be extremely difficult
to detect, and (b) result in substantial competitive harm to the business of AgeX or a Related Company. Employee has accepted
the limitations of this Section as a reasonably practicable and unrestrictive means of preventing such use or disclosure of Confidential
Information and preventing such competitive harm.

 

4.
Inventions/Intellectual Property/Confidential Information

 

(a)
Employee acknowledges the execution and delivery to AgeX of an Employee Confidential Information and Inventions Assignment
Agreement (the “Confidentiality and IP Agreement”).

 

(b)
Execution of Documents; Power of Attorney. Employee agrees to execute and sign any and all applications, assignments,
or other instruments which AgeX or a Related Company may deem necessary in order to enable AgeX or a Related Company, at its expense,
to apply for, prosecute, and obtain patents of the United States or foreign countries for the Intellectual Property, or in order
to assign or convey to, perfect, maintain or vest in AgeX or a Related Company the sole and exclusive right, title, and interest
in and to the Intellectual Property. If AgeX or a Related Company is unable after reasonable efforts to secure Employee’s
signature, cooperation or assistance in accordance with the preceding sentence, whether because of Employee’s incapacity
or any other reason whatsoever, Employee hereby designates and appoints AgeX or any Related Company or its designee as Employee’s
agent and attorney-in-fact, to act on Employee’s behalf, to execute and file documents and to do all other lawfully permitted
acts necessary or desirable to perfect, maintain or otherwise protect AgeX’s or a Related Company’s rights in the
Intellectual Property. Employee acknowledges and agrees that such appointment is coupled with an interest and is irrevocable.

 

(c)
Confidential and Proprietary Information. During Employee’s employment, Employee will have access to trade
secrets and confidential information of AgeX and one or more Related Companies. Confidential Information means all information
and ideas, in any form, relating in any manner to matters such as: products; formulas; technology and know-how; inventions; clinical
trial plans and data; business plans; marketing plans; the identity, expertise, and compensation of employees and contractors;
systems, procedures, and manuals; customers; suppliers; joint venture partners; research collaborators; licensees; and financial
information. Confidential Information also shall include any information of any kind, whether belonging to AgeX, a Related Company,
or any third party, that AgeX or a Related Company has agreed to keep secret or confidential under the terms of any agreement
with any third party. Confidential Information does not include: (i) information that is or becomes publicly known through lawful
means other than unauthorized disclosure by Employee; (ii) information that was rightfully in Employee’s possession prior
to Employee’s employment with AgeX and was not assigned to AgeX or a Related Company or was not disclosed to Employee in
Employee’s capacity as a director or other fiduciary of AgeX or a Related Company; or (iii) information disclosed to Employee,
after the termination of Employee’s employment by AgeX, without a confidential restriction by a third party who rightfully
possesses the information and did not obtain it, either directly or indirectly, from AgeX or a Related Company, and who is not
subject to an obligation to keep such information confidential for the benefit of AgeX, a Related Company, or any third party
with whom AgeX or a Related Company has a contractual relationship. Employee understands and agrees that all Confidential Information
shall be kept confidential by Employee both during and after Employee’s employment by AgeX or any Related Company. Employee
further agrees that Employee will not, without the prior written approval by AgeX or a Related Company, disclose any Confidential
Information, or use any Confidential Information in any way, either during the term of Employee’s employment or at any time
thereafter, except as required by AgeX or a Related Company in the course of Employee’s employment. To the extent any terms
between this Agreement and the Confidentiality and IP Agreement conflict, the Confidentiality and IP Agreement’s terms control.

 

    	3

    	 

    

 

5.
Termination of Employment. Employee understands and agrees that Employee’s employment has no specific term. This Agreement,
and the employment relationship, are “at will” and may be terminated by Employee or by AgeX (and the employment
of Employee by any Related Company by be terminated by the Related Company) with or without cause at any time by notice given
orally or in writing. Except as otherwise agreed in writing or as otherwise provided in this Agreement, upon termination of Employee’s
employment, AgeX and the Related Companies shall have no further obligation to Employee by way of compensation or otherwise as
expressly provided in this Agreement or in any separate employment agreement that might then exist between Employee and a Related
Company.

 

(a)
Payments Due Upon Termination of Employment. Upon termination of Employee’s employment with AgeX and all Related
Companies at any time and for any reason, Employee will be entitled to receive only the severance benefits set forth below, but
Employee will not be entitled to any other compensation, award, or damages with respect to Employee’s employment or termination
of employment.

 

(i)
Termination for Cause, Death, Disability, or Resignation. In the event of the termination of Employee’s employment
by AgeX for Cause, or termination of Employee’s employment as a result of death, Disability, or resignation, Employee will
be entitled to receive payment for all accrued but unpaid salary actually earned prior to or as of the date of termination of
Employee’s employment, and vacation or paid time off accrued as of the date of termination of Employee’s employment.
Employee will not be entitled to any cash severance benefits or additional vesting of any stock options or other equity or cash
awards.

 

(ii)
Termination Without Cause. In the event of termination of Employee’s employment by AgeX without Cause, Employee
will be entitled to (A) the benefits set forth in paragraph (a)(i) of this Section, and (B) payment in an amount equal to: (1)
three months’ base salary if terminated within the first 12 months of employment, or (2) six months’ base salary if
terminated after 12 months of employment, either of which may be paid in a lump sum or, at the election of AgeX, in installments
consistent with the payment of Employee’s salary while employed by AgeX, subject to such payroll deductions and withholdings
as are required by law. This paragraph shall not apply to (x) termination of Employee’s employment by a Related Company
if Employee remains employed by AgeX, or (y) termination of Employee’s employment by AgeX if Employee remains employed by
a Related Company.

 

    	4

    	 

    

 

(iii)
Change of Control. In the event AgeX (or any successor in interest to AgeX that has assumed AgeX’s obligation
under this Agreement) terminates Employee’s employment without Cause “ or Employee resigns for “Good Reason”
within twelve (12) months following a Change in Control, Employee will be entitled to (A) the benefits set forth in paragraph
(a)(i) and (a)(ii) of this Section, and (B) accelerated vesting of (x) fifty percent of any then unvested stock options as may
have been granted to Employee by AgeX if termination of employment occurs during the first year of Employee’s employment
by AgeX, or (y) accelerated vesting of one hundred percent (100%) of any then unvested stock options as may have been granted
to Employee by AgeX if termination of employment occurs after the first year of Employee’s employment by AgeX. This paragraph
shall not apply to (x) termination of Employee’s employment by a Related Company if Employee remains employed by AgeX or
a successor in interest, or (y) termination of Employee’s employment by AgeX or a successor in interest if Employee remains
employed by a Related Company.

 

(b)
Release. Any other provision of this Agreement notwithstanding, paragraphs (a)(ii) and (a)(iii) of this Section
shall not apply unless the Employee (i) has executed a general release of all claims against AgeX or its successor in interest
and the Related Companies (in a form prescribed by AgeX or its successor in interest), (ii) has returned all property in the Employee’s
possession belonging AgeX or its successor in interest and any Related Companies, and (iii) if serving as a director of AgeX or
any Related Company, has tendered her written resignation as a director as provided in Section 7.

 

(c)
Definitions. For purposes of this Section, the following definitions shall apply:

 

(i)
“Affiliated Group” means (A) a Person and one or more other Persons in control of, controlled by, or under common
control with such Person; and (B) two or more Persons who, by written agreement among them, act in concert to acquire Voting Securities
entitling them to elect a majority of the directors of AgeX.

 

(ii)
“Cause” means: (A) the failure to properly perform Employee’s job responsibilities, as determined reasonably
and in good faith by the Board of Directors; (B) commission of any act of fraud, gross misconduct or dishonesty with respect to
AgeX or any Related Company; (C) conviction of, or plea of guilty or “no contest” to, any felony, or a crime involving
moral turpitude; (D) breach of any provision of this Agreement or any provision of any proprietary information and inventions
agreement with AgeX or any Related Company; (E) failure to follow the lawful directions of the Board of Directors of AgeX or any
Related Company; (F) chronic alcohol or drug abuse; (G) obtaining, in connection with any transaction in which AgeX, any Related
Company, or any of AgeX’s affiliates is a party, a material undisclosed financial benefit for Employee or for any member
of Employee’s immediate family or for any corporation, partnership, limited liability company, or trust in which Employee
or any member of Employee’s immediate family owns a material financial interest; or (H) harassing or discriminating against,
or participating or assisting in the harassment of or discrimination against, any employee of AgeX (or a Related Company or an
affiliate of AgeX) based upon gender, race, religion, ethnicity, or nationality.

 

    	5

    	 

    

 

(iii)
“Change of Control” means (A) the acquisition of Voting Securities of AgeX by a Person or an Affiliated Group
entitling the holder thereof to elect a majority of the directors of AgeX; provided, that an increase in the amount of Voting
Securities held by a Person or Affiliated Group who on the date of this Agreement beneficially owned (as defined in Section 13(d)
of the Securities Exchange Act of 1934, as amended, and the regulations thereunder) more than 10% of the Voting Securities shall
not constitute a Change of Control; and provided, further, that an acquisition of Voting Securities by one or more Persons acting
as an underwriter in connection with a sale or distribution of such Voting Securities shall not constitute a Change of Control
under this clause (A); (B) the sale of all or substantially all of the assets of AgeX; or (C) a merger or consolidation of AgeX
with or into another corporation or entity in which the stockholders of AgeX immediately before such merger or consolidation do
not own, in the aggregate, Voting Securities of the surviving corporation or entity (or the ultimate parent of the surviving corporation
or entity) entitling them, in the aggregate (and without regard to whether they constitute an Affiliated Group) to elect a majority
of the directors or persons holding similar powers of the surviving corporation or entity (or the ultimate parent of the surviving
corporation or entity); provided, however, that in no event shall any transaction described in clauses (A), (B) or (C) be a Change
of Control if all of the Persons acquiring Voting Securities or assets of AgeX or merging or consolidating with AgeX are one or
more Related Companies.

 

(iv)
“Disability” shall mean Employee’s inability to perform the essential functions of Employee’s job
responsibilities for a period of one hundred eighty (180) days in the aggregate in any twelve (12) month period.

 

(v)
“Good Reason” means (A) a diminution in Employee’s base salary; (B) a material change in geographic location
at which Employee must perform services (a change in location of the AgeX office at which Employee will primarily work will be
considered material only if it increases Employee’s current one-way commute by more than fifty (50) miles); (C) any material
failure of the successors to AgeX after a Change of Control to perform, or causing AgeX not to perform, AgeX’ obligations
under this Agreement; (D) any action or inaction of AgeX that constitutes a material breach of the terms of this Agreement; or
(E) any other material adverse change in Employee’s duties, authorities, responsibilities, or reporting structure (for example,
if Employee is required to report to anyone other than a Chief Executive Officer or the Board of Directors of AgeX or its successor).

 

(vi)
“Person” means any natural person or any corporation, partnership, limited liability company, trust, unincorporated
business association, or other entity.

 

(vii)
“Voting Securities” means shares of capital stock or other equity securities entitling the holder thereof to regularly
vote for the election of directors (or for person performing a similar function if the issuer is not a corporation), but does
not include the power to vote upon the happening of some condition or event which has not yet occurred.

 

6.
Turnover of Property and Documents on Termination. Employee agrees that on or before termination of Employee’s employment,
Employee will return to AgeX and all Related Companies all equipment and other property belonging to AgeX and the Related Companies,
and all originals and copies of Confidential Information (in any and all media and formats, and including any document or other
item containing Confidential Information) in Employee’s possession or control, and all of the following (in any and all
media and formats, and whether or not constituting or containing Confidential Information) in Employee’s possession or control:
(a) lists and sources of customers; (b) proposals or drafts of proposals for any research grant, research or development project
or program, marketing plan, licensing arrangement, or other arrangement with any third party; (c) reports, job or laboratory notes,
specifications, and drawings pertaining to the research, development, products, patents, and technology of AgeX and any Related
Companies; (d) any and all Intellectual Property developed by Employee during the course of employment; and (e) the Manual and
memoranda related to the Policies.

 

    	6

    	 

    

 

7.
Arbitration. It is the intention of Employee and AgeX that the Federal Arbitration Act and the California Arbitration Act
shall apply with respect to the arbitration of disputes, claims, and controversies pursuant to, arising under, or in connection
with this Agreement. Except for injunctive proceedings against unauthorized disclosure of Confidential Information, any and all
disputes, claims, or controversies between AgeX or any Related Company and Employee, including but not limited to (a) those involving
the construction, application, or enforceability of any of the terms, provisions, or conditions of this Agreement (including but
not limited to the applicability and enforceability of provisions of this Section 7 with respect to any dispute, claim, or controversy)
or the Policies; (b) all contract or tort claims of any kind; and (c) any claim based on any federal, state, or local law, statute,
regulation, or ordinance, including claims for unlawful discrimination or harassment, shall be settled by arbitration in accordance
with the then current Employment Dispute Resolution Rules of the American Arbitration Association. Judgment on the award rendered
by the arbitrator(s) may be entered by any court having jurisdiction over the Company and Employee. The location of the arbitration
shall be San Francisco, California. Unless AgeX or a Related Company and Employee mutually agree otherwise, the arbitrator shall
be a retired judge selected from a panel provided by the American Arbitration Association, or the Judicial Arbitration and Mediation
Service (JAMS). AgeX, or a Related Company if the Related Company is a party to the arbitration proceeding, shall pay the arbitrator’s
fees and costs. Employee shall pay for Employee’s own costs and attorneys’ fees, if any. AgeX and any Related Company
that is a party to an arbitration proceeding shall pay for its own costs and attorneys’ fees, if any. However, if any party
prevails on a statutory claim which affords the prevailing party attorneys’ fees, the arbitrator may award reasonable attorneys’
fees and costs to the prevailing party.

 

EMPLOYEE UNDERSTANDS AND AGREES THAT THIS AGREEMENT
TO ARBITRATE CONSTITUTES A WAIVER OF EMPLOYEE’S RIGHT TO A TRIAL BY JURY OF ANY MATTERS COVERED BY THIS AGREEMENT TO ARBITRATE.

 

8.
Severability. In the event that any of the provisions of this Agreement or the Policies shall be held to be invalid or unenforceable
in whole or in part, those provisions to the extent enforceable and all other provisions shall nevertheless continue to be valid
and enforceable as though the invalid or unenforceable parts had not been included in this Agreement or the Policies. In the event
that any provision relating to a time period of restriction shall be declared by a court of competent jurisdiction to exceed the
maximum time period such court deems reasonable and enforceable, then the time period of restriction deemed reasonable and enforceable
by the court shall become and shall thereafter be the maximum time period.

 

9.
Agreement Read and Understood. Employee acknowledges that Employee has carefully read the terms of this Agreement, that Employee
has had an opportunity to consult with an attorney or other representative of Employee’s own choosing regarding this Agreement,
that Employee understands the terms of this Agreement, and that Employee is entering this agreement of Employee’s own free
will.

 

10.
Complete Agreement, Modification. This Agreement is the complete agreement between Employee and AgeX on the subjects contained
in this Agreement. This Agreement supersedes and replaces all previous correspondence, promises, representations, and agreements,
if any, either written or oral with respect to Employee’s employment by AgeX or any Related Company and any matter covered
by this Agreement. No provision of this Agreement may be modified, amended, or waived except by a written document signed both
by AgeX and Employee.

 

    	7

    	 

    

 

11.
Governing Law. This Agreement shall be construed and enforced according to the laws of the State of California.

 

12.
Assignability. This Agreement, and the rights and obligations of Employee and AgeX under this Agreement, may not be assigned
by Employee. AgeX may assign any of its rights and obligations under this Agreement to any successor or surviving corporation,
limited liability company, or other entity resulting from a merger, consolidation, sale of assets, sale of stock, sale of membership
interests, or other reorganization, upon condition that the assignee shall assume, either expressly or by operation of law, all
of AgeX’s obligations under this Agreement.

 

13.
Survival. This Section 13 and the covenants and agreements contained in Sections 4 and 6 of this Agreement shall survive termination
of this Agreement and Employee’s employment.

 

14.
Notices. Any notices or other communication required or permitted to be given under this Agreement shall be in writing and
shall be mailed by certified mail, return receipt requested, or sent by next business day air courier service, or personally delivered
to the party to whom it is to be given at the address of such party set forth on the signature page of this Agreement (or to such
other address as the party shall have furnished in writing in accordance with the provisions of this Section 14).

 

[Signature
Page to the Employment Agreement Follows]

 

    	8

    	 

    

 

IN
WITNESS WHEREOF, Employee and AgeX have executed this Agreement on the day and year first above written.

 

	EMPLOYEE:	 	 
	 	/s/
    Hal Sternberg	 
		Signature,
    Hal Sternberg, Ph.D. 	 
	 	 	 
	Address:	1010
    Atlantic Ave	 
	 	Alameda,
    CA 94501	 

 

AGEX:

 

	AgeX
    Therapeutics, Inc.	 
	 	 	 
	By:	/s/
    Michael D. West	 
	 	Michael
    D. West	 
	 	 	 
	Title:	Chief
    Executive Officer	 
	Address:	1010
    Atlantic Avenue, Suite 102	 
	 	Alameda,
    California 94501	 

 

[Signature
Page to the Employment Agreement]

 

    	9

    	 

    

 

EXHIBIT
A

 

Job
Title: Vice President, Research, AgeX Therapeutics, Inc.

 

Description
of Job and Duties: Dr. Sternberg is Vice President of Research and will report to the CEO of AgeX and manage basic research
programs in the company relating to pluripotent stem cell-based therapeutics and induced tissue regeneration. Dr. Sternberg will
manage laboratory personnel, prepare and analyze resulting data, and prepare and analyze such data for scientific publications,
patent applications, and for product development.

 

Annual
Salary: $235,000

 

Bonus:
Any bonus will be at the discretion of the Company’s Board of Directors or its Compensation Committee and will be based
on the attainment of Company performance goals and milestones as the Board of Directors or its Compensation Committee may
set.

 

Stock
Options: Employee shall be entitled to receive such number of options to purchase Company common shares under the
Company’s Equity Incentive Plan (the “Plan”) as the Company’s Board of Directors or Compensation
Committee may determine. The exercise price of the options shall be the fair market value of the Company’s common
shares on the effective date of grant determined in accordance with the Plan. The date of grant of the options shall be the
date on which Employee’s employment has commenced under this Agreement. Employee shall execute a stock option agreement
consistent with the terms of the option grant and the Plan. The options shall vest and thereby become exercisable, and the
options shall expire, as provided in the Plan and the terms of the option grant.

 

Paid
Time Off: Employee shall be entitled to a total of twenty-five (25) paid time off days per annum (accrued on a biweekly
pay period basis) as “paid time off” for vacation, three (3) days sick leave, and all company observed holidays.

 

    	10EX-4.1

 EXHIBIT 4.1 

CITIBANK CREDIT CARD ISSUANCE TRUST 

Citiseries 
 Class 2018-A4 Notes 
 Issuer Certificate 

Pursuant to Sections 202 and 301(h) of the Indenture 

Reference is made to the Second Amended and Restated Indenture dated as of September 26, 2000, as amended and restated as of
August 9, 2011, and as further amended and restated as of November 10, 2016, between Citibank Credit Card Issuance Trust (the “Issuer”) and Deutsche Bank Trust Company Americas, as trustee (as so further amended and restated, the
“Indenture”). Capitalized terms used herein that are not otherwise defined have the meanings set forth in the Indenture. All references herein to designated Sections are to the designated Sections of the Indenture. 

Section 301(h) provides that the Issuer may from time to time create a tranche of Notes either by or pursuant to an Issuer Certificate
setting forth the principal terms thereof. Pursuant to this Issuer Certificate, there is hereby created a tranche of Notes having the following terms: 

Series Designation: Citiseries. This series is included in Group 1. 

Tranche Designation: $600,000,000 Floating Rate Class 2018-A4 Notes of June 2023 (Legal Maturity Date June
2025) (hereinafter, the “Class 2018-A4 Notes”) 
 Currency: The
Class 2018-A4 Notes will be payable, and denominated, in Dollars. 
 Denominations: The Class 2018-A4 Notes will be issuable in minimum denominations of $100,000 and multiples of $1,000 in excess of that amount. 

Issuance Date: June 8, 2018 
 Initial Principal
Amount: $600,000,000 
 Issue Price: 100% 

Interest Rate: The Class 2018-A4 Notes will accrue interest with respect to any interest period at a per
annum rate equal to the Class 2018-A4 Note Rate for such interest period, calculated on the basis of the actual number of days in such interest period divided by 360. The
“Class 2018-A4 Note Rate” means, with respect to the first interest period, 2.36961% per annum and, with respect to each interest period thereafter, a per annum rate equal to LIBOR for such
interest period plus 0.34%. 
 The Issuer will determine LIBOR for each applicable interest period on the second business day before the beginning each
interest determination date which is two business days before the beginning of that interest period. For purposes of determining LIBOR, a business day is any day on which dealings in deposits in U.S. Dollars are transacted in the London interbank
market. The “Designated Maturity” means one month. 

 “LIBOR” means, as of any date of determination, the rate for deposits in U.S. Dollars for the
Designated Maturity (commencing on the first day of the relevant interest period) which appears on the Reuters Screen LIBOR01 Page as of 11:00 a.m., London time, on such date. Reuters Screen LIBOR01 Page” means the display page
currently so designated on the Reuters service for the purpose of displaying the London interbank offered rates of major banks for U.S. Dollars (or any other page as may replace that page on that service or any successor service displaying the
London interbank offered rates of major banks for U.S. Dollars). If such rate does not appear on the Reuters Screen LIBOR01 Page, the rate for that day will be determined on the basis of the rates at which deposits in U.S. Dollars are offered by
four major banks in the London interbank market selected by the Issuer (the “Reference Banks”) at approximately 11:00 a.m., London time, on that day to prime banks in the London interbank market for the Designated Maturity
(commencing on the first day of the relevant interest period). The Issuer will request the principal London office of each of the Reference Banks to provide a quotation of its rate. If at least two such quotations are provided, the rate for that day
will be the arithmetic mean of the quotations. If fewer than two quotations are provided as requested, the rate for that day will be the arithmetic mean of the rates quoted by three major banks in New York City, selected by the Issuer, at
approximately 11:00 a.m., New York City time, on that day for loans in U.S. Dollars to leading European banks for a period of the Designated Maturity (commencing on the first day of the relevant interest period). If fewer than three New York
City banks selected by the Issuer are quoting rates as provided in the immediately preceding sentence, then the rate for the applicable date of determination for the current interest period will be the same as the rate determined for the immediately
preceding date of determination for the immediately preceding interest period. 
 Notwithstanding anything in the preceding three paragraphs herein under
“Interest Rate:” or in the Indenture to the contrary, if, on or prior to any interest determination date, Citibank, N.A. (or one of its affiliates) determines that LIBOR has been discontinued or is permanently no longer being published,
the Issuer will use a substitute or successor base rate that Citibank, N.A. (or one of its affiliates) has determined, in its sole discretion after consulting any source it deems to be reasonable, is (a) the industry-accepted substitute or
successor base rate or (b) if there is no such industry-accepted substitute or successor base rate, a substitute or successor base rate that is most comparable to LIBOR. Upon selection of a substitute or successor base rate, Citibank, N.A. (or
such affiliate) may determine, in its sole discretion after consulting any source it deems to be reasonable, the day count, the business day convention, the definition of business day, the interest determination date and any other relevant
methodology for calculating such substitute or successor base rate, including any adjustment factor it determines is needed to make such substitute or successor base rate comparable to LIBOR, in a manner that is consistent with industry-accepted
practices for such substitute or successor base rate. 
 Scheduled Interest Payment Dates: The 7th day of each month, beginning July 9, 2018.

 Each payment of interest on the Class 2018-A4 Notes will include all interest accrued from and including the
preceding Interest Payment Date — or, for the first interest period, from and including the Issuance Date — to and including the day preceding the current Interest Payment Date, plus any interest accrued but not previously paid.

  
 2 

 The first deposit targeted to be made to the Interest Funding sub-Account for the
Class 2018-A4 Notes will be on the July 6, 2018 Interest Deposit Date and in an amount equal to $1,224,298.50. 

Expected Principal Payment Date: June 7, 2023 

Legal Maturity Date: June 9, 2025 
 Monthly
Principal Date: For the month in which the Expected Principal Payment Date occurs, June 7, 2023, and for each other month, the 7th day of such month, or if such day is not a Business Day, the next following Business Day. 

Required Subordinated Amount of Class B Notes: $35,897,460.00 

Required Subordinated Amount of Class C Notes: $47,863,260 

Controlled Accumulation Amount: $50,000,000 
 Form of
Notes: The Class 2018-A4 Notes will be issued as Global Notes. The Global Notes will initially be registered in the name of Cede & Co., as nominee of The Depository Trust Company, and will be
exchangeable for individual Notes only in accordance with the provisions of Section 204(c). 
 Additional Issuances of Class 2018-A4 Notes: The Issuer may at any time and from time to time issue additional Class 2018-A4 Notes, subject to the satisfaction of (i) the conditions
precedent set forth in Section 311(a) and (ii) the following conditions: 
  

	 	(a)	The Issuer has obtained written confirmation from each Rating Agency that there will be no Ratings Effect with respect to the then outstanding Class 2018-A4 Notes as a result
of the issuance of such additional Class 2018-A4 Notes; 

  

	 	(b)	As of the date of issuance of the additional Class 2018-A4 Notes, all amounts due and owing to the Holders of the then outstanding
Class 2018-A4 Notes have been paid and there is no Nominal Liquidation Amount Deficit with respect to the then outstanding Class 2018-A4 Notes;

  

	 	(c)	The additional Class 2018-A4 Notes will be fungible with the original Class 2018-A4 Notes for federal income tax purposes;

  

	 	(d)	If Holders of the then outstanding Class 2018-A4 Notes have the benefit of a Derivative Agreement, the Issuer will have obtained a Derivative Agreement for the benefit of the
Holders of the additional Class 2018-A4 Notes; and 

  

	 	(e)	The ratio of the Controlled Accumulation Amount to the Initial Dollar Principal Amount of the Class 2018-A4 Notes, including the additional
Class 2018-A4 Notes, will be equal to the ratio of the Controlled Accumulation Amount (before giving effect to the additional issuance) to the Initial Dollar Principal Amount of the Class 2018-A4 Notes, excluding the additional Class 2018-A4 Notes. 

  
 3 

 As of the date of issuance of additional Class 2018-A4 Notes, the
Outstanding Dollar Principal Amount and Nominal Liquidation Amount of the Class 2018-A4 Notes will be increased to reflect the Initial Dollar Principal Amount of the additional Class 2018-A4 Notes. 
 Any outstanding Class 2018-A4 Notes and any
additional Class 2018-A4 Notes will be equally and ratably entitled to the benefits of the Indenture without preference, priority or distinction. 

Optional Redemption Provisions other than Section 1202 “Clean-Up Call”: None 

Additional Early Redemption Events or changes to Early Redemption Events: None 

Additional Events of Default or changes to Events of Default: None 

Business Day: means any day other than (a) a Saturday or Sunday or (b) any other day on which national banking associations or state banking
institutions in New York, New York or South Dakota, or any other state in which the principal executive offices of any Additional Seller are located, are authorized or obligated by law, executive order or governmental decree to be closed. 

Securities Exchange Listing: None 

  
 4 

 The Class 2018-A4 Notes shall have such other terms
as are set forth in the form of Note attached hereto as Exhibit A. Pursuant to Section 202, the form of Note attached hereto has been approved by the Issuer. 

 

			
	CITIBANK CREDIT CARD ISSUANCE TRUST
	By	 	Citibank, N.A.,
		 	as Managing Beneficiary
		
	 	 	/s/ Bennett L. Kyte
		 	    Bennett L. Kyte
		 	    Vice President

 Dated: June 8, 2018 

  
 5 

 Citiseries 

Class 2018-A4 Notes 

Reference is made to the resolutions adopted by the Board of Directors of Citibank, N.A. on January 18, 2018, and April 25, 2018.
The resolutions authorize Citibank, N.A. from time to time to issue and sell, or to arrange for or participate in the issuance and sale of, one or more series and/or classes of pass-through certificates, participation certificates, commercial paper,
notes, bonds or other securities representing ownership interests in, or backed or secured by, pools of credit card receivables or interests therein (the “Receivables”) in an aggregate principal amount such that up to $45,000,000,000 of
such certificates, commercial paper, notes, bonds or other securities are outstanding at any one time and to sell, transfer, convey, assign or pledge or grant a security interest in all or any portion of its Receivables to Citibank Credit Card
Master Trust I, Citibank Omni Trust or any direct or indirect subsidiaries of Citibank, N.A., affiliates of Citigroup Inc., additional trusts or other entities or trustees in connection therewith on such terms as to be determined by the Citibank,
N.A. Securitization Pricing and Loan Committee (the “Pricing and Loan Committee”). 
 The undersigned, a duly authorized member of
the Pricing and Loan Committee, on behalf of such Pricing and Loan Committee, does hereby certify that the preceding Issuer Certificate, the terms of the tranche of Notes set forth in and to be created by the Issuer Certificate and the increase in
the Invested Amount of the Collateral Certificate resulting from the issuance of such Notes have been approved by such Pricing and Loan Committee. In addition, the following underwriting/selling agent terms with respect to this tranche of Notes have
been approved by the Pricing and Loan Committee: 
 Issue Price: 100% 

Underwriting Commission: 0.275% 

Proceeds to Issuer: 99.725% 

Representative of the Underwriters: Citigroup Global Markets Inc. 

The preceding Issuer Certificate and this certification of Pricing and Loan Committee approval shall be, continuously from the time of their
execution, official records of Citibank, N.A. 
  

	
	
	/s/ Bennett L. Kyte
	Bennett L. Kyte
	Member of the Securitization Pricing and Loan Committee
	Citibank, N.A.

 Dated: June 8, 2018 

  
 6 

 Exhibit A 

FORM OF 
 CITISERIES 

FLOATING RATE CLASS 2018-A4 NOTES OF JUNE 2023 

(Legal Maturity Date June 2025) 
  

			
	$[    ],000,000	  	REGISTERED
	CUSIP No. 17305E GN9	  	No. R-[1][2]

 UNLESS THIS NOTE IS PRESENTED BY AN AUTHORIZED REPRESENTATIVE OF THE DEPOSITORY TRUST COMPANY, A NEW YORK
CORPORATION (“DTC”), TO THE ISSUER OR ITS AGENT FOR REGISTRATION OF TRANSFER, EXCHANGE OR PAYMENT, AND ANY NOTE ISSUED IS REGISTERED IN THE NAME OF CEDE & CO. OR IN SUCH OTHER NAME AS IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE
OF DTC (AND ANY PAYMENT IS MADE TO CEDE & CO. OR TO SUCH OTHER ENTITY AS IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF DTC), ANY TRANSFER, PLEDGE OR OTHER USE HEREOF FOR VALUE OR OTHERWISE BY OR TO ANY PERSON IS WRONGFUL INASMUCH AS THE
REGISTERED OWNER HEREOF, CEDE & CO., HAS AN INTEREST HEREIN. 
 THE PRINCIPAL OF THIS NOTE IS PAYABLE AS SET FORTH HEREIN AND IN THE
INDENTURE REFERRED TO BELOW. ACCORDINGLY, THE OUTSTANDING PRINCIPAL AMOUNT OF THIS NOTE AT ANY TIME MAY BE LESS THAN THE AMOUNT SHOWN ON THE FACE HEREOF. 

CITIBANK CREDIT CARD ISSUANCE TRUST 

CITISERIES 
 FLOATING RATE CLASS 2018-A4 NOTES OF JUNE 2023 
 (Legal Maturity Date June 2025) 

CITIBANK CREDIT CARD ISSUANCE TRUST, a trust formed and existing under the laws of the State of Delaware (including any successor, the “Issuer”),
for value received, hereby promises to pay to CEDE & CO., or its registered assigns, the principal amount of [    ] HUNDRED MILLION DOLLARS ($[    ],000,000). The Expected Principal Payment Date for
this Note is June 7, 2023. The Legal Maturity Date for this Note is June 9, 2025. 
 The Issuer hereby promises to pay interest on this Note on
the 7th day of each month, beginning July 2018, until the principal of this Note is paid or made available for payment, subject to certain limitations set forth in the Indenture. Interest will accrue on the outstanding principal amount of this Note
for each interest period in an amount equal to the product of (i) the actual number of days in such interest period divided by 360, (ii) a rate per annum equal to the Class 2018-A4 Note Rate for such
interest period, and (iii) the outstanding principal amount of this Note as of the preceding Interest Payment Date (after giving effect to any payments of principal made on the preceding Interest Payment Date) or, with respect to the first
Interest Payment Date, the initial principal amount of this Note. The Class 2018-A4 Note Rate will be determined as provided in the Indenture. 

 If any Interest Payment Date or Principal Payment Date of this Note falls on a day that is not a Business Day,
the required payment of interest or principal will be made on the following Business Day. 
 This Note is one of the Citiseries, Class 2018-A4 Notes issued pursuant to the Second Amended and Restated Indenture dated as of September 26, 2000, as amended and restated as of August 9, 2011, and as further amended and restated as of
November 10, 2016 (as so further amended and restated and otherwise modified from time to time, the “Indenture”), between the Issuer and Deutsche Bank Trust Company Americas, as Trustee. For purposes of this Note, the term
“Indenture” includes any supplemental indenture or Issuer Certificate relating to the Citiseries, Class 2018-A4 Notes. This Note is subject to all of the terms of the Indenture. All terms used
in this Note that are not otherwise defined herein and that are defined in the Indenture will have the meanings assigned to them therein. 
 The principal
of and interest on this Note are payable in such coin or currency of the United States of America as at the time of payment is legal tender for payment of public and private debts. 

Reference is made to the further provisions of this Note set forth on the reverse hereof, which will have the same effect as though fully set forth on the
face of this Note. 
 Unless the certificate of authentication hereon has been executed by the Trustee whose name appears below by manual signature, this
Note will not be entitled to any benefit under the Indenture, or be valid or obligatory for any purpose. 

 IN WITNESS WHEREOF, the Issuer has caused this instrument to be signed, manually or in facsimile, by an Issuer
Authorized Officer. 
  

			
	CITIBANK CREDIT CARD ISSUANCE TRUST
		
	By:	 	CITIBANK, N.A.,
		 	 as Managing Beneficiary of
 Citibank Credit
Card Issuance Trust

		
	By:	 	 
		 	Bennett L. Kyte
		 	Vice President

 Dated: June 8, 2018 

TRUSTEE’S CERTIFICATE OF AUTHENTICATION 

This is one of the Notes designated above and referred to in the within mentioned Indenture. 

 

			
	 DEUTSCHE BANK TRUST COMPANY AMERICAS,

as Trustee under the Indenture

		
	By:	 	 
		 	 Authorized Signatory

 Dated: June 8, 2018 

 REVERSE OF NOTE 

This Note is one of a duly authorized issue of Notes of the Issuer, designated as its Citiseries Floating Rate
Class 2018-A4 Notes of June 2023 (Legal Maturity Date June 2025) (herein called the “Notes”), all issued under an Indenture, to which Indenture reference is hereby made for a statement of the
respective rights and obligations thereunder of the Issuer, the Trustee and the Holders of the Notes. 
 This Note ranks pari passu with all other
Class A Notes of the same series, as set forth in the Indenture. This Note is secured to the extent, and by the collateral, described in the Indenture. 

The Issuer will pay interest on overdue interest as set forth in the Indenture to the extent lawful. 

Each Holder by acceptance of this Note, and each owner of a beneficial interest in this Note by acceptance of a beneficial interest in this Note, agrees that
no recourse may be taken, directly or indirectly, with respect to the obligations of the Issuer or the Trustee on the Notes, against the Issuer, the Issuer Trustee, Citibank, N.A., the Trustee or any affiliate, officer, employee or director of any
of them, and the obligation of the Issuer to pay principal of or interest on this Note or any other amount payable to the Holder of this Note will be subject to Article V of the Indenture. 

Each Holder by acceptance of this Note, and each owner of a beneficial interest in this Note by acceptance of a beneficial interest in this Note, in each case
other than Citibank, N.A. as Holder or owner, agrees that this Note is intended to be debt of Citibank, N.A. for federal, state and local income and franchise tax purposes, and agrees to treat this Note accordingly for all such purposes, unless
otherwise required by a taxing authority. 
 Each Holder by acceptance of this Note, and each owner of a beneficial interest in this Note by acceptance of a
beneficial interest in this Note, agrees that it will not at any time institute against the Issuer, or join in any institution against the Issuer of, any bankruptcy, reorganization, arrangement, insolvency or liquidation proceeding, or other
proceedings under any United States federal or state bankruptcy or similar law in connection with any obligations relating to this Note, the Indenture or any Derivative Agreement. 

This Note and the Indenture will be construed in accordance with and governed by the laws of the State of New York. 

Certain amendments may be made to the Indenture without the consent of the Holder of this Note. This Note must be surrendered for final payment of principal
and interest. 

 ASSIGNMENT 

Social Security or taxpayer I.D. or other identifying number of assignee:__________________________________ 

FOR VALUE RECEIVED, the undersigned hereby sells, assigns and transfers unto 

 
  

 
  

(name and address of assignee) 
 the within Note
and all rights thereunder, and hereby irrevocably constitutes and appoints ____________________________________ ______________________, attorney, to transfer said Note on the books kept for registration thereof, with full power of substitution in
the premises. 
  

									
					
	Dated:	 	   
	 		 	*	 	
		 		 		 	Signature Guaranteed:	 	

  

	*	NOTE: The signature to this assignment must correspond with the name of the registered owner as it appears on the face of the within Note in every particular without alteration, enlargement or any change whatsoever.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00284-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00284-of-00352.parquet"}]]